Kimberly-Clark has completed its acquisition of Kenvue, the consumer health company behind Tylenol, Band-Aid, Zyrtec, Neutrogena and Listerine. The transaction values Kenvue at nearly $49 billion, including debt, and expands Kimberly-Clark’s presence in health and wellness products.
The company reaffirmed its financial targets for the deal on Monday. Kimberly-Clark expects to reduce costs and expenses by $1.9 billion within three years. It also anticipates $500 million in additional profit from higher revenue, partly offset by $300 million in planned reinvestment.
Kimberly-Clark shares rose 0.3% on Monday to close at $108.25. The company’s recent stock performance has prompted investors to focus on how effectively it can integrate Kenvue and deliver the expected benefits.
Chief Executive Officer Michael Hsu said accelerating Kenvue’s growth will be a central priority. Kimberly-Clark plans to apply its experience in retailer relationships, digital operations, advertising and product development to areas where Kenvue has room to improve, including its e-commerce strategy and the development of existing product categories.
Kenvue was separated from Johnson & Johnson and became an independent company in May 2023. Hsu said Kimberly-Clark believes it has more developed consumer-packaged-goods capabilities and can combine them with Kenvue’s brands to support faster growth.
The combined company will also have to manage higher input costs linked to the Iran war while keeping products affordable for lower- and middle-income consumers. Hsu said Kimberly-Clark expects to offset commodity inflation through pricing over time, while also reducing costs and maintaining its focus on value products. He cited improvements to the value-tier Huggies Snug & Dry diapers as one example.
Tylenol brings additional legal and reputational challenges. More than 500 lawsuits alleging that prenatal Tylenol use contributed to autism or ADHD in children were revived in July after a federal appeals court found that expert testimony had been improperly excluded. A U.S. appeals court later declined to reconsider that decision.
Hsu said Kimberly-Clark reviewed scientific, medical and legal issues before proceeding with the acquisition. He defended Tylenol’s safety and effectiveness, saying the brand had regained momentum after a modest sales impact from the controversy in 2025. He also pointed to Tylenol with Naproxen, which became the first and only over-the-counter pain reliever combining acetaminophen and naproxen sodium to receive FDA approval in July.
Kimberly-Clark has also pledged to preserve its dividend. The company has raised its payout for at least 50 consecutive years and had a dividend yield of 4.73% based on Monday’s closing price. Although it is taking on debt to help finance the cash-and-stock transaction, Hsu said the dividend remains secure.
The company expects earnings to be accretive by the second year after the acquisition and aims to reduce leverage to about 2.0 while maintaining its single-A credit rating. Hsu said Kimberly-Clark’s broader objective is to create long-term shareholder value while preserving its record of dividend growth.
Sources: CNBC Markets.